Chase Pharmaceuticals Corp. said that it has appointed Douglas Ingram, a former president of Allergan Inc., which was based in Irvine, as its chief executive.
Washington, D.C.-based Chase is developing drugs for Alzheimer’s disease. Ingram replaces John Siebert, who is continuing as senior advisor for Chase.
Ingram was Allergan’s president until it was acquired earlier this year by Ireland-based Actavis PLC for $72.5 billion. He also had served as president of Allergan’s Europe, Middle East and Africa region and had other executive roles with the drug maker.
